25803-68-3Relevant academic research and scientific papers
Practical synthesis of β-carbonyl phenyltetrazolesulfones and investigations of their reactivities in organocatalysis
Zweifel, Theo,Nielsen, Martin,Overgaard, Jacob,Jacobsen, Christian Borch,Jorgensen, Karl Anker
supporting information; experimental part, p. 47 - 52 (2011/03/18)
A practical synthesis of β-carbonyl phenyltetrazolesulfones, useful for a series of enantioselective reactions, is shown. Aryl, alkyl and ester carbonyl compounds all proved to be efficiently synthesised, leading to products in up to >99% yield over two s
Modulation of 11β-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles
Webster, Scott P.,Binnie, Margaret,McConnell, Kirsty M.M.,Sooy, Karen,Ward, Peter,Greaney, Michael F.,Vinter, Andy,Pallin, T. David,Dyke, Hazel J.,Gill, Matthew I.A.,Warner, Ines,Seckl, Jonathan R.,Walker, Brian R.
scheme or table, p. 3265 - 3271 (2010/09/14)
Inhibitors of 11β-hydroxysteroid dehydrogenase (11β-HSD1) show promise as drugs to treat metabolic disease and CNS disorders such as cognitive impairment. A series of 1,5-substituted 1H-tetrazole 11β-HSD1 inhibitors has been discovered and chemically modified. Compounds are selective for 11β-HSD1 over 11β-HSD2 and possess good cellular potency in human and murine 11β-HSD1 assays. A range of in vitro stabilities are observed in human liver microsome assays.
1,5-SUBSTITUTED TETRAZOLES AS THERAPEUTIC COMPOUNDS
-
Page/Page column 67, (2010/11/26)
The present invention pertains to certain 1,5-substituted-1H-tetrazole compounds that, inter alia, inhibit 11β- hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, bothin vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat conditions that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes conditions such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS conditions such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
Kinetics and Mechanism of the Alkaline Release of Phenyl(mercapto)tetrazoles from α-Oximes
Boggs, Roger A.,Hasan, Fariza B.,Mahoney, J. Barry,Mehta, Avi C.,Palumbo, Catherine M. K.,et al.
, p. 1271 - 1277 (2007/10/02)
Compounds such as α-phenyl(mercapto)tetrazole (PMT) oxime (9) undergo rapid elimination of the PMT anion in base via a nitrosoene intermediate.Solution kinetics and HPLC analysis of reaction products are consistent with the mechanism shown in Scheme 2.For open chain oximes such as 4, substitution α to the oxime increases the rate of release of PMT and is attributed to the relief of strain when a crowded reactant is converted to a less-crowded product.For cyclic oximes, the six-membered ring compounds are more reactive than the corresponding five-membered compounds.A linear isokinetic relationship between the entropy and enthalpy of activation was found with β = 346 +/- 51 K.Entropies of activation were found to range from -7 to +24 c.u. (1 c.u. = 4.184 J mol-1 K-1) and support the proposed mechanism.
